TABLE I -.

Maximum drops in the notified LPs experienced by the analysed oncologic drugs, first drops experienced, and time intervals passed until reaching the minimum notified LP since the approval of the LP of the first generic medicine

Drug	Patent expiration Date	First descent notified LP	Maximum descent notified LP	Years to minimum LP
Vinorelbine	Not available	−37%	−56%	4.3
Capecitabine	14/12/2013	−39%	−68%	1.9
Imatinib	01/12/2016	−40%	−97%	4.6
Pemetrexed	10/06/2021	−40%	−45%	4.4
Erlotinib	01/03/2020	−42%	−74%	1.1
Dasatinib	01/11/2019	−69%	−70%	1.3
Gefitinib	01/09/2019	−40%	−84%	1.1
Everolimus	17/01/2019	−58%	−66%	1.7

LP = list price.